• 1
    Arber DA, Brunning RD, Le Beau MM, et al. Acute myeloid leukaemia with recurrent genetic abnormalities. In: Swerdlow SH, Campo E, Harris NL, eds. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008: 110-123.
  • 2
    Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100: 4325-4336.
  • 3
    Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000; 96: 4075-4083.
  • 4
    Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998; 58: 4173-4179.
  • 5
    Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998; 92: 2322-2333.
  • 6
    Pui CH. Toward optimal central nervous system-directed treatment in childhood acute lymphoblastic leukemia. J Clin Oncol. 2003; 21: 179-181.
  • 7
    Jeha S, Pei D, Raimondi SC, et al. Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia. 2009; 23: 1406-1409.
  • 8
    Bassan R, Gatta G, Tondini C, Willemze R. Adult acute lymphoblastic leukaemia. Crit Rev Oncol Hematol. 2004; 50: 223-261.
  • 9
    Mayadev JS, Douglas JG, Storer BE, Appelbaum FR, Storb R. Impact of cranial irradiation added to intrathecal conditioning in hematopoietic cell transplantation in adult acute myeloid leukemia with central nervous system involvement. Int J Radiat Oncol Biol Phys. 2011; 80: 193-198.
  • 10
    Johnston DL, Alonzo TA, Gerbing RB, Lange BJ, Woods WG. The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: a Children's Oncology Group study. Pediatr Blood Cancer. 2010; 55: 414-420.
  • 11
    Sirvent N, Suciu S, Rialland X, et al. Prognostic significance of the initial cerebro-spinal fluid (CSF) involvement of children with acute lymphoblastic leukaemia (ALL) treated without cranial irradiation: results of European Organization for Research and Treatment of Cancer (EORTC) Children Leukemia Group study 58881. Eur J Cancer. 2011; 47: 239-247.
  • 12
    Trujillo JM, Cork A, Ahearn MJ, Youness EL, McCredie KB. Hematologic and cytologic characterization of 8/21 translocation acute granulocytic leukemia. Blood. 1979; 53: 695-706.
  • 13
    International System for Human Cytogenetic Nomenclature (ISCN). An International System for Human Cytogenetics Nomenclature. Basel, Switzerland: S. Karger; 1995.
  • 14
    Stasi R, Del Poeta G, Masi M, et al. Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia. Cancer Genet Cytogenet. 1993; 67: 28-34.
  • 15
    Bloomfield CD, Goldman A, Hassfeld D, de la Chapelle A. Fourth International Workshop on Chromosomes in Leukemia 1982: clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia. Cancer Genet Cytogenet. 1984; 11: 332-350.
  • 16
    Holmes R, Keating MJ, Cork A, et al. A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(p13q22). Blood. 1985; 65: 1071-1078.
  • 17
    Billstrom R, Ahlgren T, Bekassy AN, et al. Acute myeloid leukemia with inv(p13q22): involvement of cervical lymph nodes and tonsils is common and may be a negative prognostic sign. Am J Hematol. 2002; 71: 15-19.
  • 18
    Larson RA, Williams SF, Le Beau MM, Bitter MA, Vardiman JW, Rowley JD. Acute myelomonocytic leukemia with abnormal eosinophils and inv or t(16;16) has a favorable prognosis. Blood. 1986; 68: 1242-1249.
  • 19
    Glass JP, Van Tassel P, Keating MJ, Cork A, Trujillo J, Holmes R. Central nervous system complications of a newly recognized subtype of leukemia: AMML with a pericentric inversion of chromosome 16. Neurology. 1987; 37: 639-644.
  • 20
    Johnston DL, Alonzo TA, Gerbing RB, Lange BJ, Woods WG. Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia. J Clin Oncol. 2005; 23: 9172-9178.
  • 21
    Chang H, Brandwein J, Yi QL, Chun K, Patterson B, Brien B. Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. Leuk Res. 2004; 28: 1007-1011.
  • 22
    Peterson BA, Brunning RD, Bloomfield CD, et al. Central nervous system involvement in acute nonlymphocytic leukemia. A prospective study of adults in remission. Am J Med. 1987; 83: 464-470.
  • 23
    Ravandi F, Cortes J, Faderl S, et al. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood. 2010; 116: 5818-5823; quiz 6153.
  • 24
    Yanada M, Jinnai I, Takeuchi J, et al. Clinical features and outcome of T-lineage acute lymphoblastic leukemia in adults: a low initial white blood cell count, as well as a high count predict decreased survival rates. Leuk Res. 2007; 31: 907-914.
  • 25
    Hoelzer D, Gokbuget N. Recent approaches in acute lymphoblastic leukemia in adults. Crit Rev Oncol Hematol. 2000; 36: 49-58.
  • 26
    Martin G, Barragan E, Bolufer P, et al. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFβ/MYH11 rearrangement. Haematologica. 2000; 85: 699-703.